AstraZeneca PLC

Report azionario LSE:AZN

Capitalizzazione di mercato: UK£204.7b

AstraZeneca Crescita futura

Criteri Future verificati 4/6

AstraZeneca prevede che gli utili e i ricavi cresceranno rispettivamente di 13.5% e 6.3% all'anno. Si prevede che l'EPS crescerà di 14.3% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 28.5% in 3 anni.

Informazioni chiave

13.5%

Tasso di crescita degli utili

14.29%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili9.9%
Tasso di crescita dei ricavi6.3%
Rendimento futuro del capitale proprio28.55%
Copertura analitica

Good

Ultimo aggiornamento15 Jun 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Aggiornamento della narrazione • Jun 03

AZN: Recent Drug Approvals And Key Readouts Will Support Bullish Repricing

Analysts have lifted their AstraZeneca price targets by up to £1,000 per share, pointing to updated valuation work that reflects Baxfendy's FDA approval, recent price target revisions from several banks, and slight tweaks to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research around AstraZeneca clusters into two camps, with some analysts leaning more optimistic after Baxfendy's approval and a series of price target moves, while others highlight execution and regulatory questions that could affect how those targets are met.
Aggiornamento della narrazione • Apr 29

AZN: Pipeline Readouts And 2H26 Catalyst Path Will Drive Bullish Repricing

AstraZeneca's analyst price targets have been raised in recent research, with moves such as Guggenheim's lift to £160.00 and Citi's and Morgan Stanley's increases in their London based targets, as analysts point to refreshed models, updated earnings views and a more constructive stance on the pipeline. Analyst Commentary Recent research around AstraZeneca centres on refreshed valuation work, updated earnings paths and how the pipeline feeds into longer term growth expectations.
Aggiornamento della narrazione • Apr 15

AZN: Updated Oncology Pipeline Outlook Will Support Multi Year Re Rating

Analysts have lifted their AstraZeneca price targets, with several recent moves in the £500 to £1,000 range. They cite stronger confidence in the earnings outlook and pipeline after updated models and conference follow ups.
Aggiornamento della narrazione • Apr 01

AZN: 1H26 Trial Cluster Will Test Sustained Premium Earnings Expectations

AstraZeneca's updated analyst price target reflects a modest uplift, with the fair value estimate moving from £117.29 to £124.85 as analysts factor in refreshed models after recent results, a higher assumed future P/E of about 25x, and ongoing optimism around the earnings pipeline highlighted in recent research. Analyst Commentary Recent research on AstraZeneca has included a series of price target revisions, with several large banks updating their models following full year results and subsequent investor events.
Aggiornamento della narrazione • Mar 18

AZN: Oncology Pipeline And Breast Cancer Trial Readouts Will Support Re Rating

Analysts have lifted AstraZeneca's fair value estimate from £182.81 to £205.97 and raised several price targets, citing updated models, a higher assumed profit margin and a more constructive view on the earnings pipeline. Analyst Commentary Recent Street research points to a cluster of upbeat views on AstraZeneca, with several bullish analysts revisiting their models and adjusting price targets after fresh company updates and sector readthroughs.
Aggiornamento della narrazione • Mar 03

AZN: Oncology Pipeline And 2H26 Catalysts Will Shape Balanced Long-Term Outlook

The updated analyst price target for AstraZeneca increases to £162.67 from £152.79. This reflects broader Street research that highlights stronger earnings potential and a more constructive view on the company’s pipeline and long term growth drivers.
Aggiornamento della narrazione • Feb 17

AZN: Elevated Margin Assumptions Will Face Pressure From Pipeline And Competition Risks

Narrative Update: AstraZeneca Analyst Price Target Shift Analysts have raised their fair value estimate for AstraZeneca from £108.53 to £117.29, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple, supported by recent price target increases and fresh bullish coverage across several banks. Analyst Commentary Recent Street research on AstraZeneca has leaned positive, with several banks adjusting fair value estimates and starting coverage with supportive views.
Aggiornamento della narrazione • Feb 03

AZN: Oncology Pipeline And Manufacturing Investments Will Shape Balanced Long-Term Outlook

Analysts have lifted their AstraZeneca fair value estimate to £152.79 from £150.26, reflecting higher price targets from several firms and updated views on the company’s revenue growth, profit margins and future P/E assumptions. Analyst Commentary Recent Street research on AstraZeneca has been active, with several bullish analysts lifting price targets and initiating positive coverage.
Aggiornamento della narrazione • Jan 20

AZN: Oncology Pipeline And 2030 Sales Ambition Will Support Re Rating

Narrative Update The analyst price target for AstraZeneca has been nudged higher to reflect a fair value estimate of £182.81 per share, with analysts pointing to supportive Street research that includes recent target upgrades from Deutsche Bank and Barclays, as well as constructive commentary on oncology and the broader biopharma pipeline. Analyst Commentary Recent Street research reflects a cluster of bullish analysts lifting price targets on AstraZeneca, with several pointing to oncology and the broader biopharma pipeline as key parts of their constructive view.
Aggiornamento della narrazione • Jan 06

AZN: Oncology And Biopharma Execution Will Offset Patent Pressure Concerns

AstraZeneca's implied fair value has shifted from £173.72 to £182.32 as analysts weigh stronger confidence in oncology and broader biopharma sales potential against concerns about approaching patent pressures and a less certain pipeline in breast cancer. Analyst Commentary Recent research shows a split in views, but bullish analysts see room for AstraZeneca's valuation to reflect stronger confidence in oncology and biopharma execution, even as others flag upcoming patent risks and breast cancer pipeline uncertainty.
Aggiornamento della narrazione • Dec 14

AZN: Oncology Execution And US Manufacturing Expansion Will Drive Long-Term Upside Potential

Analysts have nudged their fair value estimate for AstraZeneca higher to approximately $150.26 from about $146.44, reflecting confidence that the company can deliver on its long term, oncology driven growth ambitions despite mixed views on patent risk and pipeline momentum. Analyst Commentary Recent Street research highlights a sharp divergence in views on AstraZeneca, with some bullish analysts emphasizing the durability of its oncology growth engine and others warning that the valuation already discounts too optimistic a pipeline and patent outcome.
Aggiornamento della narrazione • Nov 28

AZN: Oncology Pipeline Execution And Patent Expiry Risks Will Define Long-Term Prospects

AstraZeneca's analyst price target was revised slightly higher from £145.43 to £146.44, as analysts cite optimism around the company's oncology franchises and biopharma pipeline. Some remain cautious given upcoming patent pressures and mixed views on pipeline outlook.
Aggiornamento della narrazione • Nov 14

AZN: Oncology Pipeline Momentum And Patent Pressures Will Shape Outlook Amid Policy Changes

AstraZeneca's analyst price target has inched higher from $144.38 to $145.43, as analysts cite ongoing strength in its oncology franchises and biopharma pipeline, along with improved margin expectations. Analyst Commentary Recent Street research on AstraZeneca reflects a wide range of perspectives on the company's outlook, with both bullish and bearish analysts voicing key points of emphasis around valuation, pipeline potential, and execution risks.
Articolo di analisi • Nov 13

AstraZeneca's (LON:AZN) Performance Is Even Better Than Its Earnings Suggest

AstraZeneca PLC's ( LON:AZN ) strong earnings report was rewarded with a positive stock price move. We have done some...
Aggiornamento della narrazione • Oct 31

AZN: In-Market Oncology And U.S. Drug Pricing Will Shape Long-Term Performance

AstraZeneca's analyst-derived fair value has been raised to $144.38 per share from $140.96. This reflects modest increases in pipeline confidence and anticipated revenue growth, as noted by analysts in recent research updates.
Aggiornamento della narrazione • Oct 17

Breakthrough Pipeline Therapies And Emerging Markets Will Create Lasting Success

AstraZeneca's analyst price target has been raised from £138.16 to £140.96. This reflects a modest increase as analysts highlight both expanding potential for key pipeline products and a tempered outlook on patent risk and competitive pressures in certain therapeutic areas.
Aggiornamento della narrazione • Oct 03

Breakthrough Pipeline Therapies And Emerging Markets Will Create Lasting Success

AstraZeneca’s analyst price target has been raised from $93 to $99. Analysts cite stronger pipeline progress and improved revenue growth forecasts as key factors for the upward revision.

Previsioni di crescita degli utili e dei ricavi

LSE:AZN - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/202871,55616,13715,22021,01121
12/31/202767,15714,13713,73919,16325
12/31/202663,32112,48810,43216,83524
3/31/202660,43910,3897,91914,221N/A
12/31/202558,73910,2258,80614,575N/A
9/30/202558,1279,3999,67915,140N/A
6/30/202556,5018,2958,32713,389N/A
3/31/202554,9827,7729,19513,088N/A
12/31/202454,0737,0357,39811,861N/A
9/30/202451,2066,4956,86711,334N/A
6/30/202449,1336,4407,04511,065N/A
3/31/202447,6116,3315,8879,698N/A
12/31/202345,8115,9556,85810,345N/A
9/30/202344,9945,8967,27010,363N/A
6/30/202344,4856,1636,85410,179N/A
3/31/202343,8404,7056,3579,709N/A
12/31/202244,3513,2887,6849,808N/A
9/30/202245,1552,0406,5388,828N/A
6/30/202244,038-1,2535,7897,617N/A
3/31/202241,487-1,0635,7217,261N/A
12/31/202137,4171124,3505,963N/A
9/30/202132,8161,4715,1846,343N/A
6/30/202129,5283,7715,4216,446N/A
3/31/202127,5833,9774,8996,594N/A
12/31/202026,6173,1963,1444,799N/A
9/30/202025,8712,4973,2734,376N/A
6/30/202025,6992,1483,0573,657N/A
3/31/202025,2471,5222,7893,495N/A
12/31/201924,3841,335N/A2,969N/A
9/30/201924,1372,056N/A3,818N/A
6/30/201923,0712,188N/A3,184N/A
3/31/201922,4032,408N/A2,371N/A
12/31/201822,0902,155N/A2,618N/A
9/30/201821,4502,422N/A1,391N/A
6/30/201822,3422,677N/A3,165N/A
3/31/201822,2382,804N/A3,350N/A
12/31/201722,4653,001N/A3,578N/A
9/30/201722,2733,542N/A4,541N/A
6/30/201721,7403,870N/A3,109N/A
3/31/201722,2923,390N/A3,040N/A
12/31/201623,0023,499N/A4,145N/A
9/30/201623,8162,465N/A2,756N/A
6/30/201624,0622,221N/A3,690N/A
3/31/201624,7662,921N/A4,589N/A
12/31/201524,7082,825N/A3,324N/A
9/30/201525,0251,696N/A4,595N/A
6/30/201525,6891,180N/A4,800N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di AZN ( 13.5% all'anno) è superiore al tasso di risparmio ( 3.4% ).

Guadagni vs Mercato: Si prevede che gli utili di AZN ( 13.5% all'anno) cresceranno più rapidamente del mercato UK ( 11.6% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di AZN cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di AZN ( 6.3% all'anno) crescerà più rapidamente del mercato UK ( 4.6% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di AZN ( 6.3% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di AZN sarà elevato tra 3 anni ( 28.5 %)

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/06/16 17:46
Prezzo dell'azione a fine giornata2026/06/16 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

AstraZeneca PLC è coperta da 56 analisti. 25 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
null nullABG Sundal Collier
John EadeArgus Research Company
Odile RundquistBaader Helvea Equity Research